论文部分内容阅读
目的 对比奥氮平与利培酮治疗精神分裂症患者的效果和安全性?方法 将我院2018 年3 月至2019 年3 月收治的130 例精神分裂症患者随机分为两组，每组65 例，研究组患者采用奥氮平治疗，对照组患者使用利培酮治疗?治疗8 周后，对两组患者的治疗效果?认知功能和不良反应进行对比?结果 治疗前，两组PANSS 各项评分比较，差异无统计学意义(P > 0.05)?治疗后，两组患者的PANSS 各项评分均优于治疗前(P 0.05)?治“,”Objective To compare the efficacy and safety of olanzapine and risperidone in the treatment of cognitive function in patients with schizophrenia. Methods From March 2018 to March 2019， 130 schizophrenic patients admitted to our hospital were randomly divided into two groups， 65 patients in each group. The study group were treated with olanzapine， and the control group were treated with risperidone. After 8 weeks of treatment， the therapeutic effect， cognitive function and adverse reactions of the two groups were compared. Results Before treatment， there was no significant difference in PANSS scores between the two groups (P >0.05). After treatment， the PANSS scores of both groups were better than those before treatment (P 0.05). After treatment， the CWT test and WCST test in the study group were better than those in the study group (P <0.05). The incidence of adverse reactions in the study group was 18.46% lower than 40.00% in the control group (P <0.05). Conclusion Olanzapine and risperidone are effective in the treatment of schizophrenia. Olanzapine is safer and better than risperidone in improving cognitive function.